What Happened?
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial results for the third quarter of 2025, showing resilient performance and robust sales growth. In its earnings report from the previous day, the company disclosed net revenues of $191.8 million for the quarter. Furthermore, its adjusted net income reached $44.7 million, which translated to $0.93 per diluted share. This performance underscored the company's strong financial health, even as it navigated challenges like increased competition and sales declines in certain product areas. The positive results appeared to give investors confidence in the company's standing.
After the initial pop the shares cooled down to $28.27, up 4% from previous close.
Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here.
What Is The Market Telling Us
Amphastar Pharmaceuticals’s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 10.9% on the news that the stock's positive momentum continued as the company reported third-quarter financial results that surpassed analyst expectations. Amphastar posted revenue of $191.8 million and adjusted earnings of $0.93 per share, beating Wall Street's consensus estimates. The strong performance was reportedly driven by robust sales of its products Baqsimi and Primatene Mist. Following the results, analyst firm Needham maintained its 'Buy' rating on the company's stock but lowered its price target to $34 from $36.
Amphastar Pharmaceuticals is down 22.2% since the beginning of the year, and at $28.27 per share, it is trading 40.7% below its 52-week high of $47.71 from November 2024. Investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,471.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.
